Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors.
暂无分享,去创建一个
Andreas Schätzlein | Chris Twelves | Carol McCormick | Ian Judson | Robert Brown | H. Mackay | A. Schätzlein | I. Judson | S. Kaye | D. Jadayel | C. Twelves | J. Plumb | G. Strathdee | Sophie Barrett | Robert Brown | S. Barrett | A. Setanoians | Stanley B Kaye | C. McCormick | Kim Appleton | Helen J Mackay | Jane A Plumb | Gordon Strathdee | Chooi Lee | Sarah Reade | Dalal Jadayel | Adrian Tang | Katharine Bellenger | Lynsay Mackay | Albert Setanoians | C. Lee | K. Appleton | K. Bellenger | L. Mackay | A. Tang | S. Reade
[1] J. Issa,et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] T. Boon,et al. Promoter-Dependent Mechanism Leading to Selective Hypomethylation within the 5′ Region of Gene MAGE-A1 in Tumor Cells , 2004, Molecular and Cellular Biology.
[3] Kun-Tsan Lin,et al. High-performance liquid chromatographic analysis of chemical stability of 5-aza-2'-deoxycytidine. , 1981, Journal of pharmaceutical sciences.
[4] John M Bennett,et al. Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.
[5] J. Herman,et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[6] C. Plass,et al. Genome-wide analysis of DNA methylation changes in human malignancies. , 2006, Current topics in microbiology and immunology.
[7] Peter A. Jones,et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. , 2002, Blood.
[8] J. Sludden,et al. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. , 2000, Cancer research.
[9] Peter A. Jones,et al. Epigenetics in human disease and prospects for epigenetic therapy , 2004, Nature.
[10] Peter A. Jones,et al. Cellular differentiation, cytidine analogs and DNA methylation , 1980, Cell.
[11] O. de Backer,et al. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[12] K. Bélanger,et al. Pilot phase I-II study on 5-aza-2'-deoxycytidine (Decitabine) in patients with metastatic lung cancer. , 1997, Anti-cancer drugs.
[13] Robert Brown,et al. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker. , 2004, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[14] Jacqueline A. Hall,et al. CpG island methylation of DNA damage response genes in advanced ovarian cancer. , 2005, Cancer research.
[15] Sandya Liyanarachchi,et al. Prognostic DNA Methylation Biomarkers in Ovarian Cancer , 2006, Clinical Cancer Research.
[16] Frank Lyko,et al. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. , 2005, Journal of the National Cancer Institute.
[17] J. Issa. Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection , 2005, Nature Clinical Practice Oncology.
[18] David A Jones,et al. Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] M. Esteller. Relevance of DNA methylation in the management of cancer. , 2003, The Lancet. Oncology.
[20] R. Lenzi,et al. Modulation of cisplatin resistance by 2'-deoxy-5-azacytidine in human ovarian tumor cell lines. , 1994, Anticancer research.
[21] M. Ehrlich,et al. Cancer-linked DNA hypomethylation and its relationship to hypermethylation. , 2006, Current topics in microbiology and immunology.
[22] S. Côté,et al. Pharmacological approach for optimization of the dose schedule of 5-Aza-2’-deoxycytidine (Decitabine) for the therapy of leukemia , 1997, Leukemia.
[23] G. Schwartsmann,et al. A Phase I Trial of Cisplatin Plus Decitabine, a New DNA-Hypomethylating Agent, in Patients with Advanced Solid Tumors and a Follow-Up Early Phase II Evaluation in Patients with Inoperable Non-Small Cell Lung Cancer , 2000, Investigational New Drugs.
[24] Jorge Cortes,et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. , 2004, Blood.
[25] R. Hoffman,et al. Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. , 2003, Blood.
[26] Robert Brown,et al. The Acquisition of hMLH1 Methylation in Plasma DNA after Chemotherapy Predicts Poor Survival for Ovarian Cancer Patients , 2004, Clinical Cancer Research.